Lindsay A Md Rosenwald is Director of Checkpoint Therapeutics, Inc.. Currently has a direct ownership of 144,812 shares of CKPT, which is worth approximately $543,045. The most recent transaction as insider was on Dec 13, 2024, when has been sold 12,638 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 145K
9.56% 3M change
188.91% 12M change
Total Value Held $543,045

LINDSAY A MD ROSENWALD Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 13 2024
BUY
Grant, award, or other acquisition
-
12,638 Added 8.03%
144,812 Common Stock
May 14 2024
BUY
Grant, award, or other acquisition
-
82,051 Added 38.3%
132,174 Common Stock
Jun 13 2023
BUY
Grant, award, or other acquisition
-
17,483 Added 25.86%
50,123 Common Stock
Jun 16 2022
BUY
Grant, award, or other acquisition
-
47,619 Added 12.73%
326,401 Common Stock
Jun 10 2021
BUY
Grant, award, or other acquisition
-
16,502 Added 5.59%
278,782 Common Stock

Also insider at

FBIO
Fortress Biotech, Inc. Healthcare
DERM
Journey Medical Corp Healthcare
MBIO
MUSTANG BIO, INC. Healthcare
ATXI
AVENUE THERAPEUTICS, INC. Healthcare
LAM

Lindsay A Md Rosenwald

Director
Scottsdale, AZ

Track Institutional and Insider Activities on CKPT

Follow Checkpoint Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CKPT shares.

Notify only if

Insider Trading

Get notified when an Checkpoint Therapeutics, Inc. insider buys or sells CKPT shares.

Notify only if

News

Receive news related to Checkpoint Therapeutics, Inc.

Track Activities on CKPT